134 related articles for article (PubMed ID: 38305197)
21. Safety of deferasirox: a retrospective cohort study on the risks of gastrointestinal, liver and renal events.
Huang WF; Chou HC; Tsai YW; Hsiao FY
Pharmacoepidemiol Drug Saf; 2014 Nov; 23(11):1176-82. PubMed ID: 24946110
[TBL] [Abstract][Full Text] [Related]
22. Deferasirox versus deferoxamine in managing iron overload in patients with Sickle Cell Anaemia: a systematic review and meta-analysis.
Qadah T
J Int Med Res; 2022 Dec; 50(12):3000605221143290. PubMed ID: 36562113
[TBL] [Abstract][Full Text] [Related]
23. Deferasirox shows in vitro and in vivo antileukemic effects on murine leukemic cell lines regardless of iron status.
Lee DH; Jang PS; Chung NG; Cho B; Jeong DC; Kim HK
Exp Hematol; 2013 Jun; 41(6):539-46. PubMed ID: 23415674
[TBL] [Abstract][Full Text] [Related]
24. Iron chelation by deferasirox confers protection against concanavalin A-induced liver fibrosis: A mechanistic approach.
Adel N; Mantawy EM; El-Sherbiny DA; El-Demerdash E
Toxicol Appl Pharmacol; 2019 Nov; 382():114748. PubMed ID: 31499193
[TBL] [Abstract][Full Text] [Related]
25. Deferasirox-induced renal impairment in children: an increasing concern for pediatricians.
Dubourg L; Laurain C; Ranchin B; Pondarré C; Hadj-Aïssa A; Sigaudo-Roussel D; Cochat P
Pediatr Nephrol; 2012 Nov; 27(11):2115-2122. PubMed ID: 22527533
[TBL] [Abstract][Full Text] [Related]
26. Five Years of Deferasirox Therapy for Cardiac Iron in β-Thalassemia Major.
Vlachaki E; Agapidou A; Spanos G; Klonizakis P; Vetsiou E; Mavroudi M; Boura P
Hemoglobin; 2015; 39(5):299-304. PubMed ID: 26177199
[TBL] [Abstract][Full Text] [Related]
27. Deferasirox and vitamin D
Ghaith MM; El-Boshy M; Almasmoum H; Abdelghany AH; Azzeh FS; Almaimani RA; Idris S; Ahmad J; Mahbub AA; BaSalamah MA; Elzubeir ME; Refaat B
J Trace Elem Med Biol; 2022 Dec; 74():127085. PubMed ID: 36179462
[TBL] [Abstract][Full Text] [Related]
28. Deferasirox reduces oxidative DNA damage in bone marrow cells from myelodysplastic patients and improves their differentiation capacity.
Jiménez-Solas T; López-Cadenas F; Aires-Mejía I; Caballero-Berrocal JC; Ortega R; Redondo AM; Sánchez-Guijo F; Muntión S; García-Martín L; Albarrán B; Alonso JM; Del Cañizo C; Hernández-Hernández Á; Díez-Campelo M
Br J Haematol; 2019 Oct; 187(1):93-104. PubMed ID: 31172513
[TBL] [Abstract][Full Text] [Related]
29. Iron chelator deferasirox inhibits NF-κB activity in hepatoma cells and changes sorafenib-induced programmed cell deaths.
Jomen W; Ohtake T; Akita T; Suto D; Yagi H; Osawa Y; Kohgo Y
Biomed Pharmacother; 2022 Sep; 153():113363. PubMed ID: 35834989
[TBL] [Abstract][Full Text] [Related]
30. Pharmacological and clinical evaluation of deferasirox formulations for treatment tailoring.
Piolatto A; Berchialla P; Allegra S; De Francia S; Ferrero GB; Piga A; Longo F
Sci Rep; 2021 Jun; 11(1):12581. PubMed ID: 34131221
[TBL] [Abstract][Full Text] [Related]
31. No difference in myocardial iron concentration and serum ferritin with deferasirox and deferiprone in pediatric patients with hemoglobinopathies: A systematic review and meta-analysis.
Saleem A; Waqar E; Shuja SH; Naeem U; Moeed A; Rais H; Ahmed J
Transfus Clin Biol; 2023 Feb; 30(1):69-74. PubMed ID: 35878782
[TBL] [Abstract][Full Text] [Related]
32. Deferasirox chelation therapy in patients with transfusion-dependent MDS: a 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata.
Maurillo L; Breccia M; Buccisano F; Voso MT; Niscola P; Trapè G; Tatarelli C; D'Addosio A; Latagliata R; Fenu S; Piccioni AL; Fragasso A; Aloe Spiriti MA; Refrigeri M; Criscuolo M; Musto P; Venditti A
Eur J Haematol; 2015 Jul; 95(1):52-6. PubMed ID: 25764148
[TBL] [Abstract][Full Text] [Related]
33. Iron Chelators, Such as Deferasirox, When Combined With Hydroxyurea, Provide an Additional Benefit of Iron Chelation in Patients Receiving Chronic Transfusion Therapy.
Manganas K; Delicou S; Xydaki A; Koskinas J
Hemoglobin; 2022 Mar; 46(2):114-117. PubMed ID: 36069257
[TBL] [Abstract][Full Text] [Related]
34. Safety and efficacy of combined chelation therapy with deferasirox and deferoxamine in a gerbil model of iron overload.
Otto-Duessel M; Brewer C; Gonzalez I; Nick H; Wood JC
Acta Haematol; 2008; 120(2):123-8. PubMed ID: 19018129
[TBL] [Abstract][Full Text] [Related]
35. Long-term improvement in cardiac magnetic resonance in β-thalassemia major patients treated with deferasirox extends to patients with abnormal baseline cardiac function.
Casale M; Filosa A; Ragozzino A; Amendola G; Roberti D; Tartaglione I; De Michele E; Cozzolino D; Rispoli G; Palmieri F; Pugliese U; Scianguetta S; Signoriello G; Musallam KM; Perrotta S
Am J Hematol; 2019 Mar; 94(3):312-318. PubMed ID: 30489651
[TBL] [Abstract][Full Text] [Related]
36. Deferasirox-TAT(47-57) peptide conjugate as a water soluble, bifunctional iron chelator with potential use in neuromedicine.
Goswami D; Vitorino HA; Alta RY; Silvestre DM; Nomura CS; Machini MT; Espósito BP
Biometals; 2015 Oct; 28(5):869-77. PubMed ID: 26164834
[TBL] [Abstract][Full Text] [Related]
37. The iron chelator deferasirox synergises with chemotherapy to treat triple-negative breast cancers.
Tury S; Assayag F; Bonin F; Chateau-Joubert S; Servely JL; Vacher S; Becette V; Caly M; Rapinat A; Gentien D; de la Grange P; Schnitzler A; Lallemand F; Marangoni E; Bièche I; Callens C
J Pathol; 2018 Sep; 246(1):103-114. PubMed ID: 29876931
[TBL] [Abstract][Full Text] [Related]
38. A 3-year study of deferasirox therapy in sickle cell disease patients in Basra, Southern Iraq.
Mohsin AM; Hassan MK
Niger J Clin Pract; 2018 Jun; 21(6):735-742. PubMed ID: 29888721
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
Kontoghiorghe CN; Kontoghiorghes GJ
Drug Des Devel Ther; 2016; 10():465-81. PubMed ID: 26893541
[TBL] [Abstract][Full Text] [Related]
40. The Oral Ferroportin Inhibitor VIT-2763 Improves Erythropoiesis without Interfering with Iron Chelation Therapy in a Mouse Model of β-Thalassemia.
Nyffenegger N; Flace A; Doucerain C; Dürrenberger F; Manolova V
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33467196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
